EINDHOVEN,
New VP Global Clinical & Regulatory –
Erika joins ONWARD from Abbott Neuromodulation, where she was Director,
“I am delighted to welcome Erika to our leadership team,” said
“I am humbled by the opportunity to help advance ONWARD’s therapies to address critical unmet needs for people who have experienced spinal cord injury. I am also thrilled to join this passionate and highly capable leadership team, which is driven to make these important therapies accessible as soon as possible,” commented
New VP, Global Marketing –
Sarah comes to ONWARD from Nevro, an implantable neuromodulation company, where she served as Head of Commercial Marketing. Prior to that, she held various leadership roles in global marketing across multiple Johnson & Johnson medical device franchises, most recently as the business unit leader for J&J’s Advanced Imaging business. Sarah earned an MBA from
“Sarah’s extensive background in the marketing of medical devices, and particularly neuromodulation therapies, will be invaluable as we prepare to commercialize our first therapy later this year,” said
“I am inspired by the ONWARD mission, and it’s an honor to join this world-class team focused on restoring function in people with spinal cord injury. I am looking forward to partnering with the clinical community to bring this game-changing therapy to market,” added
About
ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries. ONWARD’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, which can be delivered by implantable (ARC-IM) or external (ARC-EX) systems, is designed to deliver targeted, programmed spinal cord stimulation to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life.
ONWARD has received five Breakthrough Device Designations from the
ONWARD is headquartered in Eindhoven,
For Company Enquiries:
info@onwd.com
For Media Enquiries:
US:
media@onwd.com
For Investor Enquiries:
investors@onwd.com
Disclaimer
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
© OMX, source